Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 8.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 122,835 shares of the biopharmaceutical company's stock after acquiring an additional 9,606 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.22% of Agios Pharmaceuticals worth $4,036,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in AGIO. Summit Investment Advisors Inc. lifted its stake in Agios Pharmaceuticals by 7.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 5,913 shares of the biopharmaceutical company's stock worth $194,000 after purchasing an additional 394 shares during the last quarter. Federated Hermes Inc. raised its holdings in Agios Pharmaceuticals by 4.4% during the fourth quarter. Federated Hermes Inc. now owns 13,691 shares of the biopharmaceutical company's stock worth $450,000 after purchasing an additional 582 shares in the last quarter. KBC Group NV lifted its position in shares of Agios Pharmaceuticals by 30.5% during the 4th quarter. KBC Group NV now owns 2,615 shares of the biopharmaceutical company's stock worth $86,000 after buying an additional 611 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of Agios Pharmaceuticals by 1.2% in the 4th quarter. Alliancebernstein L.P. now owns 61,500 shares of the biopharmaceutical company's stock valued at $2,021,000 after buying an additional 708 shares in the last quarter. Finally, Atria Investments Inc grew its position in shares of Agios Pharmaceuticals by 6.9% in the 4th quarter. Atria Investments Inc now owns 11,365 shares of the biopharmaceutical company's stock valued at $373,000 after buying an additional 737 shares during the last quarter.

Agios Pharmaceuticals Stock Up 2.2%

AGIO stock traded up $0.75 during trading on Friday, hitting $34.33. The company had a trading volume of 376,484 shares, compared to its average volume of 667,518. The firm has a 50-day moving average price of $28.98 and a 200-day moving average price of $34.23. The firm has a market cap of $1.99 billion, a PE ratio of 3.03 and a beta of 0.73. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last announced its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The company had revenue of $8.73 million for the quarter, compared to the consensus estimate of $9.86 million. Sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on AGIO shares. Scotiabank reduced their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Finally, HC Wainwright began coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They issued a "buy" rating and a $58.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Agios Pharmaceuticals has an average rating of "Hold" and an average target price of $56.50.

Insider Activity at Agios Pharmaceuticals

In other news, Director Jacqualyn A. Fouse sold 7,497 shares of the firm's stock in a transaction on Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the sale, the director now owns 149,220 shares in the company, valued at approximately $3,864,798. This trade represents a 4.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.30% of the stock is currently owned by insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.